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Abstract 
Background: The role of chemokines in anaphylaxis is unclear.
Methods: We prospectively recruited 49 patients presenting to the emergency department with an acute episode 
of anaphylaxis and 28 healthy subjects. We measured serum levels of the chemokines CCL2, CCL5, CCL7, CCL8, CCL11, 
CCL13, CCL17, CCL21, CCL22, CCL24, and CCL26, tryptase, the absolute number of circulating basophils, monocytes, 
lymphocytes, and PMNs, and whole blood FCER1A, CPA3 and HDC gene expression at two time points: during the ana‑
phylactic episode and in convalescent samples collected approximately 3 months later. We then investigated the in vitro 
chemotactic activity of chemokines induced during anaphylaxis for the in vitro migration of the corresponding cells.
Results: Only CCL2 chemokine levels were significantly increased in anaphylaxis samples (median 514 pg/ml) 
compared to convalescent samples (284 pg/ml, P < 0.0001) and healthy subjects (279 pg/ml, P < 0.0001); there was no 
significant difference in any of the other chemokines. There was a significant positive correlation between the rates 
of increase of serum CCL2 (median [range]: 106.0% [− 44.7% to 557.4%]) and tryptase (133.8% [− 6.6% to 893.4%]; 
r = 0.68, P < 0.0001) and between the acute concentration of serum CCL2 and the acute concentration of serum 
tryptase (r = 0.77, P < 0.0001). The number of circulating basophils, but not other blood cells, significantly decreased 
during anaphylaxis (median 5.0 vs. 19.1 cells/µl in convalescent samples; P < 0.0001); a decrease in whole‑blood gene 
expression of basophil markers (P ≤ 0.0018) confirmed these changes. Anaphylactic serum enhances the in vitro 
migration of basophils via CCL2‑dependent chemotactic activity; in contrast, no CCL2‑dependent chemotactic activ‑
ity was observed for convalescent samples.
Conclusions: Our findings imply an important and specific role for CCL2‑mediated chemotactic activity in the 
pathophysiology of human anaphylaxis.
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Background
Anaphylaxis is a potentially life-threatening, rapidly pro-
gressing systemic hypersensitivity reaction, often follow-
ing exposure to a small amount of allergen, including 
insect venom, foods, and medications [1]. The major 
immunopathogenesis and pathophysiological mecha-
nisms of anaphylaxis involve IgE antibodies, effector mast 
cells, basophils and the mediators histamine, platelet-
activating factor, and cysteinyl leukotrienes [2–4]. How-
ever, anaphylaxis also induces changes in other mediators, 
including tryptase [5–7], prostaglandins [8], cytokines [6, 
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increase in CCL2 (C-C Motif Chemokine Ligand 2) levels 
during human anaphylaxis [7], with no changes demon-
strated for the chemokines CCL5 [7] and CCL11 [6, 7]. 
The chemokines CCL2, CCL5, and CCL11 are involved 
in basophil migration, with the CCR2 ligand CCL2 and 
the CCR3 ligand CCL11 eliciting the most potent migra-
tory responses [10]. Chemokines that diffuse out from 
the site of release and form a concentration gradient to 
which leukocytes respond and migrate might be involved 
in the recruitment of basophils [4] or other potential 
effector cells of anaphylaxis, including monocytes/mac-
rophages [11], neutrophils [12, 13], and platelets [14], to 
the inflamed tissue sites.
In addition to CCL2 [7], several other chemokines 
might be involved in different allergic diseases. For 
monocyte chemoattractant proteins (MCPs), an increase 
in CCL7 levels in allergic conjunctivitis [15], an increase 
in CCL8 levels in chronic/eosinophilic atopic dermatitis 
[16], and an increase in CCL13 levels in allergic rhinitis 
[17] were demonstrated. For eotaxin chemokines, CCL11 
and CCL24 levels were increased in asthma and allergic 
rhinitis [18], and CCL26 levels were increased in allergic 
rhinitis [17] and atopic skin inflammation [19]. CCL5, 
CCL17, CCL21, and CCL22 were also reported to be 
involved in asthma, atopic dermatitis, allergic rhinitis and 
drug hypersensitivity syndrome [20–25].
Given that different chemokines might be important 
in allergic diseases, we performed a series of interlinked 
studies to better understand the role of chemokines and 
their chemotactic activity in anaphylaxis. In a prospec-
tive study during and after anaphylaxis caused by Hyme-
noptera venom, medication, food, or other (idiopathic), 
we investigated the serum concentration of a large panel 
of different chemokines (CCL2, CCL5, CCL7, CCL8, 
CCL11, CCL13, CCL17, CCL21, CCL22, CCL24, and 
CCL26), which were previously described in allergic dis-
eases [6, 7, 15–25]. In whole blood samples, we measured 
the absolute numbers of circulating basophils, mono-
cytes, lymphocytes, and polymorphonuclear leukocytes 
(PMNs) and the gene expression of the basophil markers 
FCER1A, carboxypeptidase A3 (CPA3) and L-histidine 
decarboxylase (HDC). We then proceeded to analyse 
the chemotactic activity of chemokines that are induced 




We prospectively recruited 49 patients (24 females; 
age, 19–82  years; Table  1) presenting to the Emergency 
Department of University Hospital Golnik, Slovenia, with 
an acute episode of anaphylaxis (January 2017 to Octo-
ber 2019). The reaction was caused by an insect sting 
in 26 patients, by medication in 14 patients, by food in 
5 patients and by other triggers in 4 patients (idiopathic 
in 2 patients and infection in 2 patients); 21 experienced 
Mueller [26] grade IV, 16 experienced grade III, 6 expe-
rienced grade II, and 6 experienced grade I reactions 
(Table  1). We collected blood samples during the reac-
tion (at presentation to the emergency department; in 
all patients we routinely measured acute serum tryptase, 
Table  1) and convalescent samples after the anaphy-
lactic episode. None of those patients were included in 
our previous study of anaphylaxis [7]. The median time 
from the onset of symptoms to sample collection was 
100  min (range 30 to 240  min); convalescent samples 
were collected a median of 80 days after the anaphylac-
tic episode (Table 1). In 30 patients, we measured serum 
chemokines and tryptase, and in 26 patients, we meas-
ured blood absolute cell counts and gene expression (of 
those 41 patients, 15 were in both subgroups); for com-
parison, we recruited 20 healthy subjects (13 females; 
age, 20–76 years) (Additional file 1: Table S1). The serum 
of 8 anaphylactic patients and isolated basophils of 8 
healthy subjects (4 females; age, 25–44 years) were used 
for in  vitro migration experiments (Additional file  1: 
Table S1).
Ethical approval was obtained from the Slovenian 
National Medical Ethics Committee. All subjects pro-
vided written informed consent.
Serum chemokines and tryptase, absolute cell counts, 
and gene expression
We measured serum concentrations of the MCP 
chemokines CCL2/MCP-1, CCL7/MCP-3, CCL8/MCP-
2, and CCL13/MCP-4; the eotaxin chemokines CCL11/
Eotaxin, CCL24/Eotaxin-2 and CCL26/Eotaxin-3; and 
the chemokines CCL5/Rantes, CCL17/TARC, CCL21/
SLC and CCL22/MDC using ELISAs according to the 
manufacturers’ instructions (Quantikine R&D Systems, 
Minneapolis, MN, USA; Abnova, Taipei, Taiwan; and 
Biolegend, San Diego, California, CA, USA). We meas-
ured serum tryptase (ImmunoCAP, Thermo Fisher, Upp-
sala, Sweden), and concentrations that exceeded 11.4 µg/l 
were considered increased. Enumeration of circulating 
basophils (CD123+HLA-DR− cells), monocytes, lym-
phocytes, and PMNs in fresh whole blood was performed 
via flow cytometry as previously described [7, 27]. 
FCER1A, CPA3, and HDC gene expression was analysed 
in whole blood samples (PAXgene, PreAnalytiX, Hom-
brechtikon, Switzerland) as previously described [7, 27]. 
Detailed methods are provided in Additional file 1.
Cell separation and in vitro migration assays
CCR2 surface expression on basophils of healthy donors 
was determined by anti-CCR2 mAb (CD192; Miltenyi 
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Biotec, Bergisch Gladbach, Germany) staining, and 
basophils were isolated from peripheral whole blood by 
negative immunomagnetic selection (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and exactly quantified by 
absolute flow cytometry basophil counts as previously 
described (CD123+HLA-DR− cells and microbeads) [7, 
27]. For the migration assay, we used modified Boyden 
chamber and polycarbonate membrane cell culture 
inserts (Corning Inc., New York, USA). A total of 20,000 
basophils were added to the upper wells, and the samples 
to be tested were placed in the lower wells. After incuba-
tion for 30 to 150 min at 37 °C, we collected the cells that 
had migrated to the lower wells and quantified them by 
absolute basophil counts [7, 27]. Basophil migration was 
calculated by using the following equation:
Basophil migration(%) =
(
absolute number of migrated basophils/absolute number of seeded basophils
)
×100.
For control experiments, we used recombinant CCL2 
(Thermo Fisher Scientific, Massachusetts, USA). To 
block CCL2, we used anti-CCL2 neutralizing antibodies 
(Sigma-Aldrich, Missouri, USA). All experiments were 
independently performed in triplicate. Detailed methods 
are described in Additional file 1.
Statistical analysis
The distribution of the data was assessed using the 
D’Agostino test. As the majority of the data were nonpara-
metric, we used the Wilcoxon or Mann–Whitney test. P 
values were Bonferroni-corrected for the complete set of 19 
variables, and a P-value < 0.0026 was accepted as significant. 
Table 1 Characteristics of the patients




Sex, n (%) 24 female (49.0)
25 male (51.0)
Age years, average (range) 50 (19–82)
Trigger, n (%)
 Hymenoptera venom 26 (53.1)
 Medication 14 (28.6)
 Food 5 (10.2)
 Other 4 (8.2)
Time from the onset of anaphylactic symptoms to sample collection at presentation to the emergency department, 
median (IQR) in minutes
100 (69)
Convalescent sampling after anaphylactic episode, median (IQR) in days 80 (93)
Emergency treatment, n (%)
 Epinephrine 25 (51.0)
 Corticosteroids 43 (87.8)
Grade of reaction, n (%)
 Mueller I 6 (12.2)
 Mueller II 6 (14.6)
 Mueller III 16 (32.7)
 Mueller IV 21 (42.9)
Symptoms, n (%)
 Any skin feature 44 (89.8)
 Any gastrointestinal feature 15 (30.6)
 Any respiratory feature 26 (53.1)
 Hypoxemia (SpO2 ≤ 92%) 7 (14.3)
 Any cardiovascular feature 24 (49.0)
 Hypotension (SBP < 90 mmHg) 19 (38.8)
 Acute tryptase > 11.4 µg/l, n (%) 32 (65.3)
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For the cellular in  vitro migration assay, all experiments 
were independently performed in triplicate, and the results 
were compared with a t-test; a P-value < 0.05 was accepted 
as significant. To quantify associations between variables, 
we used Spearman or Pearson correlation. All analyses were 
performed using GraphPad Prism (GraphPad Software, La 
Jolla, CA, USA).
Results
The chemokine CCL2, but not other chemokines, 
is significantly increased during anaphylactic episodes
MCP chemokines CCL2/MCP‑1, CCL7/MCP‑3, CCL8/MCP‑2, 
and CCL13/MCP‑4
CCL2 concentrations measured during the anaphylac-
tic episode (median 514 pg/ml) were significantly higher 
than those measured in convalescent serum samples col-
lected later (median 80 days; 284 pg/ml; P < 0.0001; Fig. 1 
and Table  2). This marked increase (median 106.0%; 
range: − 44.7% to 557.4%) was evident in 28/30 patients 
(Fig.  2). Serum CCL2 levels during the acute episode 
were also significantly higher than those observed in 
healthy subjects (median 279 pg/ml, P < 0.0001); however, 
CCL2 levels in convalescent samples showed no differ-
ence in comparison to CCL2 levels in healthy subjects 
(Fig. 1 and Table 2). Other MCP chemokines, including 
CCL7 (median 8.9, 8.5 and 8.1 pg/ml), CCL8 (73, 69 and 
70 pg/ml) and CCL13 (113, 104 and 123 pg/ml), showed 
no differences during anaphylaxis or later compared to 
healthy subjects (Fig. 1 and Table 2).
Eotaxin chemokines CCL11/eotaxin, CCL24/eotaxin‑2 
and CCL26/eotaxin‑3
There were no differences in CCL11 (median 200, 211 and 
160 pg/ml), CCL24 (1124, 946 and 1159 pg/ml) and CCL26 
(1903, 1898 and 1877  pg/ml) between the acute and con-
valescent time points and the healthy subjects (Fig.  1 and 
Table 2).
Chemokines CCL5/Rantes, CCL17/TARC, CCL21/SLC 
and CCL22/MDC
There were no differences in CCL5 (median 40.9, 41.8 
and 47.0  ng/ml), CCL17 (342, 303 and 344  pg/ml), 
CCL21 (1179, 1099 and 938 pg/ml) and CCL22 (666, 717 
and 766 pg/ml) between the acute and convalescent time 
points and the healthy subjects (Fig. 1 and Table 2).
Increase in serum CCL2 levels highly correlates 
with an increase in serum tryptase
The median concentration of serum tryptase was signifi-
cantly higher during the anaphylactic episode (12.9 µg/l) 
than later or in healthy subjects (5.4 and 3.3 µg/l, respec-
tively; P ≤ 0.0005; Fig.  1 and Table  2). The median rate 
Fig. 1 Serum CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL21, CCL22, CCL24, CCL26, and tryptase levels in 30 patients during an acute 
anaphylactic episode and in convalescent samples collected later
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of increase of serum tryptase was 133.8% (range: − 6.6% 
to 893.4%; increase in 28/30 patients), which was com-
parable to the increase in serum CCL2 levels (Fig.  2). 
There was a significant positive correlation between the 
rates of increase of serum CCL2 and tryptase (r = 0.68, 
P < 0.0001) and between the acute concentration of serum 
CCL2 and the acute concentration of serum tryptase 
(r = 0.77, P < 0.0001; Fig. 2).
Table 2 Laboratory data of anaphylactic patients and healthy subjects
PMNs polymorphonuclear leukocytes, FCER1A α subunit of the high-affinity IgE receptor, CPA3 carboxypeptidase A3, HDC histidine decarboxylase, CCR2 C-C motif 
chemokine receptor 2, MFI mean fluorescence intensity
P values were Bonferroni-corrected, and P-value < 0.0026 was accepted as significant. Statistically significant P values are presented in boldface
a In 30 patients, we measured serum chemokines and tryptase, and in 26 patients, we measured blood absolute cell counts and gene expression (of those 41 patients, 
15 were in both subgroups); serum samples from 8 patients were used for in vitro migration experiments
b In 20 healthy subjects, we measured serum chemokines and tryptase; basophils from 8 healthy subjects were used for in vitro migration experiments
Variables median (IQR) Patients with an acute episode 












 CCL2/MCP‑1 514 (561) 284 (128) 279 (147) < 0.0001 < 0.0001 0.9726
 CCL7/MCP‑3 8.9 (2.9) 8.5 (2.1) 8.1 (1.4) 0.7549 0.1636 0.1038
 CCL8/MCP‑2 73 (56) 69 (35) 70 (19) 0.1579 0.1425 0.4226
 CCL13/MCP‑4 113 (81) 104 (88) 123 (103) 0.9032 0.3367 0.7648
 CCL11/Eotaxin 200 (174) 211 (174) 160 (60) 0.2710 0.1641 0.0555
 CCL24/Eotaxin‑2 1124 (1377) 946 (1036) 1159 (1561) 0.0940 0.8665 0.5919
 CCL26/Eotaxin‑3 1903 (88) 1898 (181) 1877 (155) 0.0412 0.1746 0.4640
 CCL5/Rantes 40,907 (34,588) 41,795 (27,011) 46,993 (33,574) 0.6669 0.7485 0.9659
 CCL17/TARC 342 (194) 303 (203) 344 (180) 0.0148 0.7093 0.1931
 CCL21/SLC 1179 (1193) 1099 (645) 938 (417) 0.2206 0.3376 0.4175
 CCL22/MDC 666 (321) 717 (251) 766 (260) 0.7045 0.8014 0.5408
Serum tryptase
 µg/l 12.9 (10.6) 5.3 (2.0) 3.3 (2.0) < 0.0001 < 0.0001 0.0005
 > 11.4 µg/l, n (%) 18 (60) 1 (3.3) 0 (0) < 0.0001 < 0.0001 1
Absolute cell count (cells/µl)
 Basophils 5.0 (7.3) 19.1 (10.9) – < 0.0001 – –
 Monocytes 396 (163) 441 (108) – 0.8417 – –
 Lymphocytes 1378 (1219) 1461 (470) – 0.3904 – –
 PMNs 3881 (2873) 2875 (1144) – 0.0388 – –
Gene expression in whole blood (fold change)
 FCER1A 0.11 (0.24) 0.40 (0.64) – 0.0002 – –
 CPA3 0.22 (0.51) 0.72 (1.16) – 0.0002 – –
 HDC 0.11 (0.30) 0.38 (0.57) – 0.0018 – –
Serum of patients used for in vitro migration assays
 Tryptase (µg/l) 22.6 (16.5) 6.4 (6.2) 4.3 (5.8) 0.0002 0.0003 0.5358
 > 11.4 µg/l, n (%) 8 (100) 0 (0) 0 (0) 0.0002 0.0002 1
 CCL2 (pg/ml) 1964 (1114) 278 (175) 302 (76) 0.0002 0.0003 0.3969
Basophils of healthy donors used for the in vitro migration assays
 Absolute count (cells/
µl)
– – 18.3 (6.3) – – –
 CCR2 expression MFI – – 353 (422) – – –
 % CCR2 + basophils – – 94 (27) – – –
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Anaphylactic episodes involve a substantial reduction 
in circulating basophils
Basophils, monocytes, lymphocytes, and PMNs
The absolute number of circulating basophils was sig-
nificantly lower during the anaphylactic episode (median 
5.0 cells/µl) than in convalescent blood samples collected 
later (19.1  cells/µl, P < 0.0001; Fig.  3 and Table  2). This 
decrease (median 65.6%, range 30.0–98.6%) was evident 
in all patients. There were no significant differences in 
the monocyte (median 396 and 441 cells/µl), lymphocyte 
(1378 and 1461 cells/µl), and PMN (3881 and 2875 cells/
µl) absolute cell counts during the acute episode 
compared to convalescent blood samples collected later 
(Fig. 3).
Gene expression of basophil markers
We observed significantly lower whole blood gene 
expression of FCER1A, CPA3, and HDC during the ana-
phylactic episode than in convalescent samples (respec-
tively; P ≤ 0.0018; Fig. 3 and Table 2). Acute whole blood 
gene expression of FCER1A, CPA3, and HDC significantly 
correlated with the acute absolute number of circulating 
basophils (r = 0.53, 0.79 and 0.81, respectively; P ≤ 0.005; 
Additional file 1: Fig. S1).
Fig. 2 Comparison and correlation between serum CCL2 and tryptase levels in 30 patients with acute anaphylactic episodes
Fig. 3 Absolute basophil, monocyte, lymphocyte and PMN counts and whole blood FCER1A, CPA3, and HDC gene expression in 26 patients 
during the acute anaphylactic episode and in convalescent samples collected later. PMNs polymorphonuclear leukocytes, FCER1A α subunit of the 
high‑affinity IgE receptor, CPA3 carboxypeptidase A3, HDC histidine decarboxylase
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Anaphylactic serum enhances the in vitro migration 
of basophils via CCL2-dependent chemotactic activity
A basophil migration assay was performed using MACS-
separated human basophils and a modified Boyden 
chamber, with quantification by absolute flow cytom-
etry basophil counts. Basophils from all healthy donors 
showed high surface expression of CCR2 (Table  2). All 
experiments were performed independently in triplicate 
(detailed information is provided in Additional file 1).
Basophil migration induced by HBSS and rCCL2
As shown in Fig. 4a, during a 150-min incubation time with 
Hank’s balanced salt solution (HBSS), only a small number 
of basophils (mean, SD), 0.8 ± 0.7%) transmigrated across 
the polycarbonate membrane. Basophil migration was sig-
nificantly enhanced by the presence of 10 nM rCCL2 and 
50 nM rCCL2 (8.1 ± 4.0% and 14.0 ± 8.1%; 150 min of incu-
bation); however, after blocking with anti-CCL2 mAbs, 
rCCL2-induced migration was almost completely inhibited 
(0.8 ± 0.6%, P = 0.036 and 0.8 ± 0.1%, P = 0.047, blocking at 
10 nM and 50 nM of rCCL2, respectively).
Basophil migration induced by anaphylactic 
and convalescent serum
We compared the effects of acute serum collected during 
the anaphylactic episode and convalescent serum collected 
later (Table 2) on basophil migration. After 150 min of incu-
bation, the number of transmigrated basophils was signifi-
cantly higher (twofold) in the presence of acute serum in the 
lower wells than in the presence of convalescent serum in 
the lower wells (mean, SD: 54.0 ± 19.3% vs. 28.3 ± 11.7%, 
respectively; P = 0.01) (Fig.  4b). The number of transmi-
grated cells increased linearly until 150  min of incubation 
and then plateaued (Fig. 4c). A neutralizing antibody against 
CCL2 significantly blocked basophil transmigration induced 
by anaphylactic serum (37.7 ± 20.8% vs. 26.1 ± 19.7%; 
P = 0.001). However, a neutralizing antibody against CCL2 
did not show any blocking effect on the chemotactic 
response induced by convalescent serum (32.5 ± 12.5% vs. 
30.7 ± 18.3%) (Fig. 4b).
Discussion
Our study demonstrated that there is a selective and sig-
nificant increase in serum CCL2 chemokine levels dur-
ing anaphylactic reactions. No significant changes were 
observed for other chemokines, which were previously 
implicated in different allergic diseases or during aller-
gic inflammation [15–25]. Thus, the chemokine patterns 
of CCL5, CCL7, CCL8, CCL11, CCL13, CCL17, CCL21, 
CCL22, CCL24, and CCL26 might be of limited impor-
tance for anaphylaxis. While activation of the pathways 
associated with multiple inflammatory cytokines, includ-
ing IL-2, IL-6, IL-10, and TNFRI, were observed during 
anaphylaxis [6, 9], the selective CCL2 chemokine cas-
cade might be important for chemotactic activity during 
anaphylactic reactions. It was recently reported that the 
CCL2-FcεRI-histone deacetylase 3 signalling axis medi-
ates passive anaphylaxis by increasing the expression of 
CCL2 in mast cells [28, 29]. After allergen stimulation, 
histone deacetylase 3 binds to FcεRI, and histone deacet-
ylase 3 increases the expression of SP1 and C-Jun, which 
bind to the promoter sequences of CCL2 to increase the 
expression of CCL2 [28, 29]. Conversely, in the absence 
of allergen stimulation, histone deacetylase 3 binds to the 
promoter sequences of CCL2 to suppress the expression 
of CCL2 [28].
Our study design and the median time between symp-
tom onset and sample collection were highly comparable 
with those of previous studies of anaphylaxis [3, 6, 7, 9, 
30]. This suggests that this is an unbiased comparison, 
including the confirmation that the chemokines CCL5 
and CCL11, which may affect other important effector 
cells of allergic inflammation such as eosinophils, are 
not induced during anaphylaxis [6, 7]. The nature of the 
management of anaphylaxis (including administration of 
high-dose corticosteroids) makes it difficult to exclude 
the potential confounding effects of treatment. How-
ever, it was previously demonstrated that serum CCL2, 
CCL5, and CCL11 levels are not affected by corticoster-
oid treatment [7]. Nevertheless, corticosteroid treatment 
or the time between symptom onset and sample collec-
tion may have affected the levels of the other measured 
chemokines.
In the present study, we could not determine the cel-
lular sources of CCL2 during anaphylaxis. However, we 
showed a highly significant positive correlation between 
elevated blood levels of acute CCL2 and tryptase and 
strong similarities between the percentage increases 
of CCL2 and tryptase from convalescent serum sam-
ples. Tryptase is largely mast cell-derived, and mature 
(See figure on next page.)
Fig. 4 a–c Effects of CCL2 and acute and convalescent serum from patients with an anaphylactic episode on basophil in vitro migration. Basophil 
migration after 150 min of incubation: a in the presence of rCCL2 in the lower wells and after CCL2 blocking and b in the presence of acute 
or convalescent serum in the lower wells and after CCL2 blocking. c Time course of basophil migration (after 30, 60, 90, 120, and 150 min of 
incubation) in the presence of acute and convalescent serum in the lower wells. All experiments were independently performed in triplicate, with 
a basophils from 5 healthy donors; b basophils from the same 5 healthy donors and serum samples from 5 patients and c basophils from 3 healthy 
donors and serum samples from 3 patients (details in Additional file 1: Table S1). HBSS Hank’s balanced salt solution
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β-tryptase is stored in mast cell granules and released 
upon mast cell activation during acute anaphylaxis [2, 
5–7]. Therefore, it is tempting to speculate that the 
blood CCL2 increase that occurs during anaphylaxis is 
IgE related and mainly mast cell derived. In vitro activa-
tion of human mast cells by anti-IgE induces secretion 
of CCL2 after 30 min of stimulation, and this increase is 
observed earlier than TNF-α, IL-13, or GM-CSF mast cell 
secretion, peaking 90 min after anti-IgE stimulation [31]. 
Furthermore, mast cell CCL2 secretion is induced at low 
allergen concentrations or in the context of low receptor 
occupancy with IgE [32], and due to the short time frame 
within which the increase in serum CCL2 was observed 
in the current and previous studies [7], rapid induction 
of CCL2 production by the allergen-IgE axis might be 
feasible. Nevertheless, CCL2 is produced by a variety of 
cell types, including endothelial cells and smooth muscle 
cells [33], astrocytes as a major source of CCL2 during 
central nervous system inflammation [34] and cancer and 
stromal cells as a major source of CCL2 in tumour micro-
environments [35]; thus, the cellular sources of CCL2 
during anaphylaxis are currently unknown. Additional 
and substantially studies of mast cell CCL2 expression 
and secretion are required to confirm this speculation.
The results of experimental allergen challenge in the 
nose, airways, and skin have demonstrated that there 
is an influx of basophils to inflammatory sites several 
hours after allergen exposure [36–39]. Furthermore, it 
was recently demonstrated that airway allergen chal-
lenge induces TLR-dependent CCL2 production in the 
lungs and that circulating basophils are recruited to the 
lungs by CCL2-mediated transendothelial migration and 
a chemotactic gradient [40]. Our study demonstrated sig-
nificantly enhanced CCL2-mediated chemotactic activity 
of anaphylactic serum for the migration of isolated baso-
phils. Conversely, no CCL2-mediated basophil chemo-
tactic activity was observed for the convalescent serum 
collected later after the reaction. The CCL2-mediated 
basophil chemotactic activity of anaphylactic serum and 
the reduction in circulating basophils during anaphylaxis, 
coupled with the previous finding that basophils are the 
granulocytes most resistant to apoptosis [41], suggest 
that anaphylaxis induces rapid CCL2-mediated basophil 
migration rather than elimination by apoptosis. Moreo-
ver, anaphylaxis-related basophil migration appears to be 
selective because no significant changes were observed 
for monocytes, lymphocytes, PMNs, or chemokines 
that may affect other effector cells, and the decreased 
gene expression of basophil markers FCER1A, CPA3 and 
HDC corroborates the flow cytometry data. Therefore, 
it is tempting to speculate that CCL2 might be mast cell 
derived and that circulating basophils influx to the sites 
where the activation and degranulation of mast cells 
occur, thereby contributing to the clinical presentation of 
the sites of allergic reaction. This is consistent with clini-
cal observations of different severities and end-organ pat-
terns of anaphylaxis, which suggest that local rather than 
generalized mast cell and/or basophil degranulation may 
predominate in some individuals [41]. However, a sub-
stantially broader assessment is needed to explore and 
confirm CCL2-mediated cellular crosstalk during acute 
allergic reactions.
Although CCL2 displays major chemotactic activity for 
monocytes and interferes with the egress of monocytes 
from the bone marrow to the circulation during homeo-
stasis and inflammation [42], no changes in circulating 
monocytes were observed during anaphylaxis. However, 
studies in mice have shown that depletion of monocytes/
macrophages can reduce anaphylaxis in both IgG-medi-
ated passive models and active models [2, 11].
Conclusion
In conclusion, our data suggest that during anaphylaxis, 
an increase in the chemokine CCL2 occurs, which corre-
lates with CCL2-mediated chemotactic activity in baso-
phils and substantial migration of circulating basophils. 
Our findings imply an important and specific role for 
CCL2 in the pathophysiology of human anaphylaxis.
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